Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	3/19/2007 5:11:05 PM
	of 10280

Sepracor downgraded to "underperform" Monday, March 19, 2007 12:56:33 PM ET Friedman,Billings,Ramsey &Co NEW YORK, March 19 (newratings.com) - Analysts at Friedman Billings downgrade Sepracor Inc (SEPR.NAS) from "market perform" to "underperform." The target price has been reduced from $58 to $43. Ahead of the Bell: Sepracor Generic versions of the sleep aid Ambien are likely to hurt Sepracor Inc.'s Lunesta, a Friedman Billings Ramsey analyst said Monday as he downgraded Sepracor shares. Analyst David Amsellem downgraded shares of Sepracor to "Underperform" from "Market Perform," and cut his price target to $43 per share from $58 based on a view of weaker Lunesta sales ahead. Amsellem said a survey of doctors showed that many of them could switch patients from Lunesta to generic forms of Ambien. "In our survey, doctors by a large margin still consider the Ambien franchise the best-in-class in terms of improving sleep onset and maintenance," Amsellem said. "Two-thirds of doctors we polled would consider switching patients already on Lunesta to generic Ambien once it becomes available in April." Ambien is made by French drug maker Sanofi-Aventis. Lunesta sales show slow growth in 2007, and are unlikely to meet Sepracor's forecast or Wall Street expectations, Amsellem said. Shares of Marlborough, Mass.-based Sepracor rose 4 cents to $47.90 in premarket electronic trading. American Depositary Shares of Sanofi-Aventis fell 28 cents to $41.83 in the premarket.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next